✦ LIBER ✦

Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis

✍ Scribed by K. M. Pantalone; M. W. Kattan; C. Yu; B. J. Wells; S. Arrigain; A. Jain; A. Atreja; R. S. Zimmerman

Book ID: 115185077
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 532 KB
Volume: 14
Category: Article
ISSN: 1462-8902
DOI: 10.1111/j.1463-1326.2012.01604.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Risk of Overall Mortality in Patient

The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy: A retrospective analysis

✍ Pantalone, K. M.; Kattan, M. W.; Yu, C.; Wells, B. J.; Arrigain, S.; Jain, A.; A 📂 Article 📅 2010 🏛 American Diabetes Association 🌐 English ⚖ 146 KB

The risk of overall mortality in patient

The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis

✍ K. M. Pantalone; M. W. Kattan; C. Yu; B. J. Wells; S. Arrigain; B. Nutter; A. Ja 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB

The risk of developing coronary artery d

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

✍ Kevin M. Pantalone; Michael W. Kattan; Changhong Yu; Brian J. Wells; Susana Arri 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 286 KB

Pantalone et al.: The risk of developing

Pantalone et al.: The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

✍ David S. H. Bell 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 75 KB

Letter to the Editor re: the Letter to t

Letter to the Editor re: the Letter to the Editor by Dr. David Samuel Henry Bell, MD regarding “The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis”

✍ Robert S. Zimmerman; Kevin Matthew Pantalone 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 82 KB